Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
gptkb:repotrectinib
|
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EX25
|
| gptkbp:chemicalFormula |
C29H32N6O2
|
| gptkbp:developer |
gptkb:Turning_Point_Therapeutics
gptkb:Bristol_Myers_Squibb |
| https://www.w3.org/2000/01/rdf-schema#label |
Augtyro
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting constipation dizziness fatigue peripheral neuropathy dysgeusia increased liver enzymes |
| gptkbp:target |
gptkb:ALK
NTRK ROS1 |
| gptkbp:usedFor |
gptkb:ROS1-positive_non-small_cell_lung_cancer
NTRK gene fusion-positive solid tumors |
| gptkbp:bfsParent |
gptkb:repotrectinib
|
| gptkbp:bfsLayer |
8
|